A pioneering clinical study has found that delivering regenerative cells to fetuses affected by spina bifida during corrective surgery may represent a "major milestone" in addressing congenital conditions.
Trial Details and Safety
The US-based trial involved six developing infants with myelomeningocele. Medical teams placed mother's placental stem cells to the surface of the developing neural column while the defect was being closed.
Critically, the stem cell application was found to be safe. The study team reported that the treatment did not lead to cancerous growths, disrupt the healing process, or impede the resolution of co-occurring hindbrain herniation.
Encouraging Results
Imaging conducted after delivery showed a complete reversal of hindbrain herniation in every participant. This favorable anatomical change is closely linked to better mobility and function.
"In the event it allows more children capable of walking who wouldn't have, it could establish itself as their standard of care," said the lead researcher. "The outcomes appear super exciting and pave the way for numerous possible novel therapies."
Broader Impact and Encouragement
Independent medical specialists indicated that subsequent studies of these apparent benefits could announce a "different age" in in-utero treatment. The possibility of ameliorating neurological damage seen in utero is considered a revolutionary objective.
Particularly welcome would be advancements for urogenital and gastrointestinal outcomes, which are typical difficulties for those diagnosed with this defect.
The Path Forward
Despite this being a first-in-human effort was small in scale, its established security and encouraging indicators offer a robust platform for larger, more comprehensive studies. The addition of cellular treatment with established fetal surgery techniques offers substantial hope for improving the prognosis for future generations with spina bifida.